GlassScriptPhysician profile
Gregory R Cohen
NPI 1275646937
$7,789.58
in general payments reported to CMS, 2019-2025
25 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,070 · 2020: $391 · 2021: $1,239 · 2022: $966 · 2023: $1,288 · 2024: $1,604 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,027 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,026.57 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,098.65 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,046.07 | 2019-2021 | |
| Abbvie INC. | $913.71 | 2022-2025 | Lumigan, Alphagan P, Durysta |
| Alcon Vision LLC | $505.06 | 2019-2024 | Wavelight Refractive Suite, Clareon, Wavelight Ex500 Excimer Laser |
| Galderma Laboratories, L.P. | $453.25 | 2019-2022 | |
| Horizon Therapeutics Plc | $452.66 | 2021-2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $451.88 | 2019-2022 | |
| Dompe US, INC. | $399.80 | 2019-2024 | Oxervate |
| Allergan, INC. | $367.45 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $331.83 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $331.49 | 2019-2024 | Veritas Vision System, Tecnis Iol |
| Rayner Intraocular Lenses Limited | $307.03 | 2023-2024 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Novartis Pharmaceuticals Corporation | $173.75 | 2020-2023 | |
| Merz North America, INC. | $172.65 | 2019 | |
| Amgen INC. | $143.87 | 2024 | Tepezza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $124.99 | 2019 | |
| Biotissue Holdings INC. | $111.59 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $97.99 | 2024 | Acthar |
| Oyster Point Pharma, INC. | $84.22 | 2022-2023 | Tyrvaya |
| Shire North American Group INC | $63.62 | 2019 | |
| Harrow Eye, LLC | $52.51 | 2024 | Vevye |
| Sight Sciences, INC. | $38.07 | 2021 | |
| Glaukos Corporation | $32.75 | 2024 | Ce-Marked Kxla System |
| Kala Pharmaceuticals, INC. | $19.62 | 2021 | |
| Ocular Therapeutix, INC. | $15.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.